“Taken together, our studies suggest that 2B010 represents an anti-CD25 mAb with unique properties in that it deleted Treg from an inflammatory environment (GVHD) as well as from the TME” “Taken ...
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
PARIS--(BUSINESS WIRE)--Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the ...
Researchers from Neoleukin Therapeutics Inc. have described NEO-TRA1, a novel CD25-targeted de novo non-α agonist of the IL-2 receptor (IL-2R) designed to selectively expand Tregs.
The EasySep™ Release Mouse CD4+ CD304+ Regulatory T-Cell Isolation Kit from STEMCELL Technologies is a mouse Treg isolation kit that targets the CD304 surface marker, which, unlike the CD25 Treg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results